Amneal has been attracting media attention from the very beginning. Both for what it does, and, more importantly, for the way it does it.

How the company balances sustained growth with its dedication to unbeatable quality and value helps make Amneal one of the most remarkable companies in the industry.

To select a collection of news items from a particular time frame, please click on the year below. Click on any of the individual headlines to open and/or download the full version of the news item or press release.

For news inquiries, please contact mediarelations@amneal.com.

2017 News

  • Amneal Biosciences Introduces Third Institutional Product
    Amneal Biosciences Introduces Third Institutional Product
    January 31
  • Amneal Introduces Alosetron Hydrochloride Tablets
    Amneal Introduces Alosetron Hydrochloride Tablets
    January 30
Amneal Biosciences Introduces Third Institutional Product
January 31

Eptifibatide Injection now available

Bridgewater, New Jersey (USA), January 31, 2017 – Amneal Biosciences has launched its third generic medication for the healthcare institutional market.

Eptifibatide Injection, an AP-rated generic equivalent to Integrilin®, is available in 20 mg (2mg/mL) and 75 mg (0.75 mg/mL) strengths, sold in 10mL and 100mL vials. The product began shipping December 28, 2016 through wholesalers, distributors and directly to the trade.

“We’re very pleased to add eptifibatide to our growing portfolio of high-quality, affordable injectable medicines,” said Charles Lucarelli, Amneal Biosciences president. “Our primary focus remains providing reliable supply to hospitals, clinics and other health facilities as these are often the first line of care for patients.”

Amneal Biosciences (www.amnealbiosciences.com), a wholly-owned subsidiary of Amneal Pharmaceuticals LLC, is dedicated to the commercialization of high-barrier-to-entry generic injectables and specialty pharmaceuticals such as oncologics, anti-infectives and supportive care for healthcare providers and patients of all ages. The company’s expertise and focus on the unique needs and logistics of this market ensure the same level of quality and service for healthcare institutions and professionals that Amneal delivers to its retail customers.

 

Click here to view the full press release.

Amneal Introduces Alosetron Hydrochloride Tablets
January 30

New Generic for Lotronex®

Bridgewater, NJ (USA), January 30, 2017 – Amneal Pharmaceuticals LLC has launched alosetron hydrochloride tablets, an AB-rated generic equivalent to Lotronex®, in 0.5 mg and 1 mg strengths. Manufactured in Brookhaven, NY, the product began shipping in 30-count bottles on January 27 through wholesalers, distributors and directly to the trade.

Alosetron hydrochloride is the second new product to ship from Amneal in the 2017 calendar year following aspirin and extended-release dipyridamole capsules. Alosetron is Amneal’s 105th molecule to be approved through the ANDA process and represents the company’s first product in this therapeutic class. The Amneal product is one of only two FDA-approved generic-equivalents for Lotronex® currently available.

Amneal’s generic received FDA approval under a Risk Evaluation and Mitigation Strategy (REMS) known as the Alosetron REMS Program. Information on this REMS Program is available at https://www.alosetronrems.com or 1-844-267-8675.

Visit http://www.amneal.com/wp-content/uploads/2017/01/AlosetronHydrochloride-pi.pdf to view full prescribing information for alosetron hydrochloride tablets.

Annual U.S. sales of Lotronex® were $50 million according to November 2016 IMS market data.

Click here to view the full press release.

News Archives